Wednesday, February 11, 2026
Engelhard strengthens strategic development with new CCSO role
Engelhard is adjusting its organization in response to changing conditions in the healthcare market. As part of this step, the company has set up a Transformation Office and introduced a new management role.
Transformation Office led by Ann-Katrin Frank
The new unit is intended to centrally drive and coordinate company-wide projects and processes that support growth and innovation. Engelhard has appointed Ann-Katrin Frank as Chief Commercial Strategy Officer (CCSO) to lead the Transformation Office.
Her responsibilities also include the company’s two commercially strategic functions, Global Marketing & Communications and International Sales & Partner Management.
Data-driven collaboration and technology adoption
According to the company, the transformation agenda focuses on more data-driven and better connected ways of working. In addition, Engelhard plans to further develop processes and workflows. Technologies such as artificial intelligence and automation are expected to contribute to efficiency gains and improved decision-making.
Internal track record
Frank has been with Engelhard for 13 years and most recently led Global Marketing & Communications, which she helped build and expand. CEO Oliver Engelhard said the new role is intended to embed transformation as a continuous, strategically managed process.
Company background
Engelhard is an OTC brand manufacturer. Its portfolio includes Prospan, Sinolpan, isla, Tyrosur and Velgastin. The company states that it manufactures in Germany and sells in more than 100 countries. Engelhard employs around 550 people and focuses on areas including respiratory and skin conditions as well as digestive complaints.
